Matinas BioPharma Holdings, Inc.(MTNB)Earnings, Financials & Key Ratios
MTNB•AMEX
Price updated Jun 19, 2026
AboutMatinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.Show more
- Revenue$0-100.0%
- EBITDA-$24M-3.5%
- Net Income-$24M-5.7%
- EPS (Diluted)-4.98+5.7%
- ROE-180.73%-120.1%
MTNB Key Insights
Matinas BioPharma Holdings, Inc. (MTNB) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.4x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Shares diluted 12.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when MTNB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MTNB Price & Volume
Matinas BioPharma Holdings, Inc. (MTNB) stock price & volume — 10-year historical chart
Loading chart...
MTNB Growth Metrics
Matinas BioPharma Holdings, Inc. (MTNB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM17.26%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM23.46%
Return on Capital
10 Years-96.79%
5 Years-64.8%
3 Years-79.3%
Last Year-151.54%
MTNB Recent Earnings
Matinas BioPharma Holdings, Inc. (MTNB) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (30%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 8, 2026Metric
Actual
Est
EPS
$0.30+77.2%
$1.32
Rev
—
$25,000
Q2 2026
Mar 31, 2026Metric
Actual
Est
EPS
$0.30+77.2%
$1.32
Rev
—
$25,000
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.40
—
Rev
—
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$1.03
—
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 8, 2026 | $0.30vs $1.32+77.2% | —vs $25,000 |
| Q2 2026 | Mar 31, 2026 | $0.30vs $1.32+77.2% | —vs $25,000 |
| Q4 2025 | Nov 10, 2025 | $0.40 | — |
| Q3 2025 | Aug 14, 2025 | $1.03 | — |
Based on last 12 quarters of dataView full earnings history →
MTNB Peer Comparison
Matinas BioPharma Holdings, Inc. (MTNB) competitors in Drug Delivery Technology Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ARQT | 3.28B | 26.21 | -201.62 | 91.34% | -0.57% | -1.41% | 0.03 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 GILD | 153.66B | 123.76 | 18.25 | 2.39% | 30.99% | 42.33% | 1.09 | |
 PTCT | 6.55B | 78.98 | 10.15 | 114.51% | -22.58% | |||
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 IDYA | 2.74B | 31.23 | -24.40 | 30.24% | -62.17% | -13.96% | 0.03 | |
 AGIO | 2.03B | 34.16 | -4.80 | 48.03% | -6.4% | -34.11% | 0.05 |
Compare MTNB vs Peers
Matinas BioPharma Holdings, Inc. (MTNB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MTNB Income Statement
Matinas BioPharma Holdings, Inc. (MTNB) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 149.69K | 119.75K | 89.81K | 158.33K | 33K | 3.19M | 1.1M | 0 | 0 |
Revenue Growth % | -100% | - | -20% | -25% | 76.29% | -79.16% | 9560.61% | -65.62% | -100% | - |
Cost of Goods Sold | 52.64K | 9.01M | 6.79M | 11.23M | 14.36M | 14.58M | 16.68M | 0 | 0 | 2.46M |
COGS % of Revenue | - | 6019.56% | 5668.04% | 12508.96% | 9068.81% | 44190.91% | 523.15% | - | - | - |
Gross Profit | -52.64K▲ 0% | -8.86M▼ 16731.6% | -6.67M▲ 24.8% | -11.14M▼ 67.1% | -14.2M▼ 27.4% | -14.55M▼ 2.5% | -13.49M▲ 7.3% | 1.1M▲ 108.1% | 0▼ 100.0% | -2.46M▲ 0% |
Gross Margin % | - | -5919.56% | -5568.04% | -12408.96% | -8968.81% | -44090.91% | -423.15% | 100% | - | - |
Gross Profit Growth % | 98.97% | -16731.57% | 24.75% | -67.14% | -27.42% | -2.46% | 7.29% | 108.12% | -100% | - |
Operating Expenses | 8.26M | 16.65M | 14.77M | 7.78M | 10.01M | 10.19M | 11.1M | 24.86M | 24.59M | 11.37M |
OpEx % of Revenue | - | 11124.61% | 12330.94% | 8658.42% | 6319.57% | 30863.64% | 348.18% | 2268.43% | - | - |
Selling, General & Admin | 4.31M | 7.64M | 7.98M | 7.78M | 10.01M | 10.19M | 11.1M | 10.37M | 8.73M | 6.94M |
SG&A % of Revenue | - | 5105.05% | 6662.9% | 8658.42% | 6319.57% | 30863.64% | 348.18% | 946.44% | - | - |
Research & Development | 3.95M | 9.01M | 6.79M | 11.23M | 14.36M | 14.58M | 16.68M | 14.49M | 11.43M | 2.46M |
R&D % of Revenue | - | 6019.56% | 5668.04% | 12508.96% | 9068.81% | 44190.91% | 523.15% | 1321.99% | - | - |
Other Operating Expenses | -16.5K | 22.03K | 56.55K | -11.23M | -14.36M | -14.58M | -16.68M | 0 | 4.43M | 915K |
Operating Income | -8.26M▲ 0% | -16.5M▼ 99.9% | -14.65M▲ 11.2% | -18.92M▼ 29.2% | -24.21M▼ 27.9% | -24.73M▼ 2.2% | -24.59M▲ 0.6% | -23.77M▲ 3.4% | -24.59M▼ 3.5% | -13.83M▲ 0% |
Operating Margin % | - | -11024.61% | -12230.94% | -21067.38% | -15288.38% | -74954.55% | -771.33% | -2168.43% | - | - |
Operating Income Growth % | 16.69% | -99.86% | 11.25% | -29.18% | -27.93% | -2.18% | 0.59% | 3.35% | -3.48% | - |
EBITDA | -8.2M | -16.4M | -14.43M | -18.59M | -23.92M | -24.45M | -24.23M | -22.82M | -23.62M | -13.6M |
EBITDA Margin % | - | -10957.4% | -12048.63% | -20701.33% | -15105.21% | -74106.06% | -760.16% | -2082.57% | - | - |
EBITDA Growth % | 16.86% | -99.91% | 12.03% | -28.86% | -28.64% | -2.25% | 0.9% | 5.81% | -3.49% | 36.73% |
D&A (Non-Cash Add-back) | 52.64K | 100.61K | 218.31K | 328.76K | 290.02K | 280K | 356K | 941K | 972K | 234K |
EBIT | -8.26M | -16.5M | -14.65M | -18.92M | -24.21M | -24.73M | -24.59M | -23.77M | -20.16M | -9.97M |
Net Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 658.4K | 658.96K | 56.55K | 1.55M | 1.76M | 1.45M | 3.59M | 824K | 262K | -3.73M |
Pretax Income | -7.6M▲ 0% | -15.84M▼ 108.5% | -14.59M▲ 7.9% | -17.37M▼ 19.1% | -22.45M▼ 29.2% | -23.28M▼ 3.7% | -21M▲ 9.8% | -22.94M▼ 9.3% | -24.33M▼ 6.1% | -17.56M▲ 0% |
Pretax Margin % | - | -10584.38% | -12183.71% | -19343.35% | -14176.98% | -70554.55% | -658.63% | -2093.25% | - | - |
Income Tax | 0 | -356.96K | -506.92K | 0 | 0 | 0 | 0 | 0 | -80K | -80K |
Effective Tax Rate % | 0% | 2.25% | 3.47% | 0% | 0% | 0% | 0% | 0% | 0.33% | 0.46% |
Net Income | -7.6M▲ 0% | -15.49M▼ 103.8% | -14.08M▲ 9.1% | -17.37M▼ 23.4% | -22.45M▼ 29.2% | -23.28M▼ 3.7% | -21M▲ 9.8% | -22.94M▼ 9.3% | -24.25M▼ 5.7% | -17.48M▲ 0% |
Net Margin % | - | -10345.91% | -11760.4% | -19343.35% | -14176.98% | -70554.55% | -658.63% | -2093.25% | - | - |
Net Income Growth % | 16.82% | -103.8% | 9.06% | -23.36% | -29.21% | -3.73% | 9.82% | -9.26% | -5.71% | 17.26% |
Net Income (Continuing) | -7.6M | -15.49M | -14.08M | -17.37M | -22.45M | -23.28M | -21M | -22.94M | -24.25M | -17.48M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -6.59▲ 0% | -8.56▼ 29.9% | -7.18▲ 16.1% | -5.37▲ 25.2% | -5.23▲ 2.6% | -5.04▲ 3.6% | -3.00▲ 40.5% | -5.28▼ 76.0% | -4.98▲ 5.7% | -3.22▲ 0% |
EPS Growth % | 25.7% | -29.89% | 16.12% | 25.21% | 2.61% | 3.63% | 40.48% | -76% | 5.68% | 23.46% |
EPS (Basic) | -6.59 | -8.56 | -7.18 | -5.37 | -5.23 | -5.04 | -3.00 | -5.28 | -4.98 | - |
Diluted Shares Outstanding | 1.15M | 1.81M | 1.96M | 2.9M | 3.94M | 4.2M | 4.34M | 4.35M | 4.87M | 5.44M |
Basic Shares Outstanding | 1.15M | 1.81M | 1.96M | 2.9M | 3.94M | 4.2M | 4.34M | 4.35M | 4.87M | 5.44M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
MTNB Balance Sheet
Matinas BioPharma Holdings, Inc. (MTNB) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 4.57M | 7.96M | 13.09M | 29.92M | 61.55M | 50.99M | 34.53M | 15.54M | 8.03M | 5.65M |
Cash & Short-Term Investments | 4.11M | 7.31M | 12.45M | 27.77M | 58.68M | 49.62M | 28.81M | 13.76M | 7.28M | 5.43M |
Cash Only | 4.11M | 7.31M | 12.45M | 22.17M | 12.43M | 21.03M | 6.88M | 4.79M | 7.28M | 5.43M |
Short-Term Investments | 0 | 0 | 0 | 5.61M | 46.25M | 28.59M | 21.93M | 8.97M | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 155.61K | 155.43K | 100K | 250K | 136K | 49.53K | 5.72M | 50K | 741K | 218K |
Total Non-Current Assets | 5.25M | 6.46M | 6.86M | 10.32M | 9.41M | 10.33M | 44.33M | 9.56M | 4.62M | 4.04M |
Property, Plant & Equipment | 356K | 1.57M | 2.04M | 5.63M | 4.86M | 5.78M | 5.73M | 5.01M | 2.16M | 1.36M |
Fixed Asset Turnover | - | 0.10x | 0.06x | 0.02x | 0.03x | 0.01x | 0.56x | 0.22x | - | 0.00x |
Goodwill | 1.34M | 1.34M | 1.34M | 1.34M | 1.34M | 1.34M | 1.34M | 1.34M | 0 | 0 |
Intangible Assets | 3.02M | 3.02M | 3.02M | 3.02M | 3.02M | 3.02M | 3.02M | 3.02M | 2.26M | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 200K | 0 | 200K | 400K |
Other Non-Current Assets | 540.99K | 535.86K | 460.89K | 336K | 199.95K | 200K | 0 | 200K | 0 | 2.69M |
Total Assets | 9.82M▲ 0% | 14.42M▲ 46.9% | 19.94M▲ 38.3% | 40.24M▲ 101.8% | 70.97M▲ 76.4% | 61.33M▼ 13.6% | 78.87M▲ 28.6% | 25.1M▼ 68.2% | 12.64M▼ 49.6% | 9.7M▲ 0% |
Asset Turnover | - | 0.01x | 0.01x | 0.00x | 0.00x | 0.00x | 0.04x | 0.04x | - | 0.00x |
Asset Growth % | 16.78% | 46.94% | 38.27% | 101.77% | 76.36% | -13.59% | 28.6% | -68.17% | -49.65% | -194.27% |
Total Current Liabilities | 1.44M | 2.22M | 2.84M | 3.1M | 3.57M | 4.35M | 4.29M | 2.62M | 2.67M | 1.5M |
Accounts Payable | 475.6K | 582.87K | 295.65K | 679.31K | 349.94K | 937K | 618K | 514K | 95K | 80K |
Days Payables Outstanding | 3.3K | 23.61 | 15.9 | 22.07 | 8.9 | 23.45 | 13.53 | - | - | 23.14 |
Short-Term Debt | 118.05K | 170.24K | 199.84K | 0 | 0 | 0 | 569K | 0 | 0 | 851K |
Deferred Revenue (Current) | 0 | 29.94K | -83.25K | 100K | 643K | 33K | 809K | 0 | 0 | 0 |
Other Current Liabilities | 11.48K | 0 | 1.63M | 862K | 329 | 899K | 585K | 271K | 4K | 564K |
Current Ratio | 3.16x | 3.58x | 4.61x | 9.66x | 17.25x | 11.73x | 8.06x | 5.93x | 3.01x | 3.78x |
Quick Ratio | 3.16x | 3.58x | 4.61x | 9.66x | 17.25x | 11.73x | 8.06x | 5.93x | 3.01x | 3.78x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 1.22M | 1.52M | 961.63K | 4.09M | 3.67M | 4.48M | 37.94M | 3.24M | 2.38M | 1.74M |
Long-Term Debt | 0 | 0 | 0 | 3.75B | 0 | 0 | 0 | 0 | 0 | 1.48M |
Capital Lease Obligations | 16.45K | 67.68K | 107.66K | 3.75M | 3.33M | 4.14M | 3.56M | 2.9M | 2.13M | 5.76M |
Deferred Tax Liabilities | 1.21M | 848.18K | 341.26K | 341K | 341.26K | 341K | 34.39M | 341K | 257K | 1.03M |
Other Non-Current Liabilities | 0 | 601.14K | 512.7K | -3.75B | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 2.67M | 3.74M | 3.8M | 7.19M | 7.24M | 8.83M | 42.23M | 5.86M | 5.05M | 3.23M |
Total Debt | 144.43K | 264.89K | 390.74K | 4.23M | 3.75M | 4.7M | 4.12M | 3.56M | 2.89M | 2.33M |
Net Debt | -3.96M | -7.04M | -12.06M | -17.94M | -8.68M | -16.33M | -2.76M | -1.23M | -4.39M | -3.1M |
Debt / Equity | 0.02x | 0.02x | 0.02x | 0.13x | 0.06x | 0.09x | 0.11x | 0.18x | 0.38x | 0.36x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.17x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.23x |
Interest Coverage | - | - | - | - | - | - | - | - | - | - |
Total Equity | 7.15M▲ 0% | 10.68M▲ 49.4% | 16.14M▲ 51.1% | 33.05M▲ 104.8% | 63.73M▲ 92.8% | 52.49M▼ 17.6% | 36.64M▼ 30.2% | 19.25M▼ 47.5% | 7.59M▼ 60.6% | 6.46M▲ 0% |
Equity Growth % | 17.75% | 49.4% | 51.11% | 104.76% | 92.83% | -17.63% | -30.21% | -47.47% | -60.56% | -236.38% |
Book Value per Share | 6.20 | 5.90 | 8.23 | 11.38 | 16.18 | 12.49 | 8.45 | 4.43 | 1.56 | 1.19 |
Total Shareholders' Equity | 7.15M | 10.68M | 16.14M | 33.05M | 63.73M | 52.49M | 36.64M | 19.25M | 7.59M | 6.46M |
Common Stock | 5.82K | 9.34K | 11.33K | 16K | 20.01K | 22K | 22K | 22K | 1K | 1K |
Retained Earnings | -35.18M | -51.27M | -65.94M | -84.38M | -107.51M | -131.63M | -152.63M | -175.57M | -199.82M | -208.88M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | -439K | -1K | 228.17K | -145K | -824K | -221K | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MTNB Cash Flow Statement
Matinas BioPharma Holdings, Inc. (MTNB) cash flow — operating, investing & free cash flow history
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -6.12M | -11.46M | -10.32M | -14.09M | -17.37M | -15.22M | -19.16M | -15.28M | -15.88M | -9.01M |
Operating CF Margin % | - | -7655.6% | -8618.96% | -15690.63% | -10969.18% | -46130.3% | -600.88% | -1393.98% | - | - |
Operating CF Growth % | 21.7% | -87.28% | 9.93% | -36.54% | -23.25% | 12.35% | -25.84% | 20.24% | -3.97% | 181.37% |
Net Income | -7.6M | -15.49M | -14.08M | -17.37M | -22.45M | -23.28M | -21M | -22.94M | -24.25M | -17.48M |
Depreciation & Amortization | 52.64K | 100.61K | 218.31K | 780.82K | 774.59K | 781K | 898K | 941K | 972K | 388K |
Stock-Based Compensation | 1.52M | 3.6M | 3.83M | 2.99M | 4.56M | 4.29M | 0 | 4.95M | 3.19M | 797K |
Deferred Taxes | 0 | -356.96K | -506.92K | 6.42K | 8.48K | 0 | 0 | 0 | -84K | 0 |
Other Non-Cash Items | 2.26K | 157.35K | 57.15K | 140 | 239.83K | 1.45M | 5.73M | 108K | 4.41M | 7.78M |
Working Capital Changes | -93.79K | 528.57K | 160.24K | -492.07K | -508.69K | 1.53M | -4.79M | 1.67M | -131K | -1.11M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -22.24K | 107.27K | -287.21K | 383.66K | -329.37K | 588K | -321K | -103K | -419K | -183K |
Cash from Investing | 0 | -942.18K | -535.92K | -6.01M | -40.67M | 16.77M | 4.88M | 13.24M | 9.21M | 820K |
Capital Expenditures | 0 | -942.18K | -535.92K | -405.6K | -5.75K | -260K | -892K | -218K | 0 | 0 |
CapEx % of Revenue | - | 629.43% | 447.53% | 451.61% | 3.63% | 787.88% | 27.98% | 19.89% | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 8.48M | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | -942.18M | -535.92M | -5.61M | -8.48M | 0 | 0 | 0 | 0 | 320K |
Cash from Financing | 7M | 15.6M | 15.87M | 29.85M | 48.05M | 6.96M | 79K | -7K | 9.17M | 3.33M |
Debt Issued (Net) | -15.94K | -17.13K | -59.18K | -81.72K | -54.67K | -30K | -20K | -7K | -5K | -3K |
Equity Issued (Net) | 1000K | 1000K | 0 | 0 | 1000K | 1000K | 99K | 0 | 1000K | 2M |
Dividends Paid | -4.39B | -608.34M | -587.14M | -2.23B | -682.8M | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 4.39B | 622.84M | 603.07M | 2.26B | 684.2M | 1.42M | 0 | 0 | 0 | 35K |
Net Change in Cash | 878.45K▲ 0% | 3.2M▲ 264.4% | 5.01M▲ 56.5% | 9.75M▲ 94.6% | -9.99M▼ 202.5% | 8.51M▲ 185.2% | -14.2M▼ 266.8% | -2.04M▲ 85.6% | 2.5M▲ 222.2% | -4.86M▲ 0% |
Free Cash Flow | -6.12M▲ 0% | -12.4M▼ 102.7% | -10.86M▲ 12.5% | -14.5M▼ 33.5% | -17.37M▼ 19.8% | -15.48M▲ 10.9% | -20.05M▼ 29.5% | -15.5M▲ 22.7% | -15.88M▼ 2.5% | -9.01M▲ 0% |
FCF Margin % | - | -8285.03% | -9066.49% | -16142.24% | -10972.81% | -46918.18% | -628.86% | -1413.87% | - | - |
FCF Growth % | 22.46% | -102.68% | 12.45% | -33.53% | -19.84% | 10.88% | -29.48% | 22.71% | -2.51% | 46.84% |
FCF per Share | -5.31 | -6.85 | -5.53 | -4.99 | -4.41 | -3.68 | -4.62 | -3.57 | -3.26 | -1.66 |
FCF Conversion (FCF/Net Income) | 0.81x | 0.74x | 0.73x | 0.81x | 0.77x | 0.65x | 0.91x | 0.67x | 0.66x | 0.52x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MTNB Key Ratios
Matinas BioPharma Holdings, Inc. (MTNB) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -114.94% | -173.69% | -105% | -70.63% | -46.39% | -40.07% | -47.11% | -82.11% | -180.73% | -270.65% |
Return on Invested Capital (ROIC) | -204.87% | -362.46% | -284.36% | -147.85% | -51.75% | -40.68% | -52.66% | -68.69% | -173.88% | -337.32% |
Gross Margin | - | -5919.56% | -5568.04% | -12408.96% | -8968.81% | -44090.91% | -423.15% | 100% | - | - |
Net Margin | - | -10345.91% | -11760.4% | -19343.35% | -14176.98% | -70554.55% | -658.63% | -2093.25% | - | - |
Debt / Equity | 0.02x | 0.02x | 0.02x | 0.13x | 0.06x | 0.09x | 0.11x | 0.18x | 0.38x | 0.36x |
FCF Conversion | 0.81x | 0.74x | 0.73x | 0.81x | 0.77x | 0.65x | 0.91x | 0.67x | 0.66x | 0.52x |
Revenue Growth | -100% | - | -20% | -25% | 76.29% | -79.16% | 9560.61% | -65.62% | -100% | - |
Related:MTNB Dividend History·MTNB Revenue History·MTNB Price History·MTNB P/E History·MTNB Financial Ratios·MTNB Institutional Holders
MTNB Frequently Asked Questions
Matinas BioPharma Holdings, Inc. (MTNB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Matinas BioPharma Holdings, Inc. (MTNB) saw revenue decline by 100.0% over the past year.
Matinas BioPharma Holdings, Inc. (MTNB) reported a net loss of $17.5M for fiscal year 2024.
Dividend & Returns
Matinas BioPharma Holdings, Inc. (MTNB) has a return on equity (ROE) of -180.7%. Negative ROE indicates the company is unprofitable.
Matinas BioPharma Holdings, Inc. (MTNB) had negative free cash flow of $9.0M in fiscal year 2024, likely due to heavy capital investments.